Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 11/20 | 0.34 |
| ▸ | GPR142 | Q7Z601 | 1/20 | 0.33 |
| ▸ | CREBBP | Q92793 | 4/20 | 0.32 |
| ▸ | KIT | P10721 | 1/20 | 0.32 |
| ▸ | AURKA | O14965 | 1/20 | 0.32 |
| ▸ | FLT1 | P17948 | 1/20 | 0.32 |
| ▸ | GCK | P35557 | 1/20 | 0.32 |
| ▸ | FLT4 | P35916 | 1/20 | 0.32 |
| ▸ | MAP3K11 | Q16584 | 1/20 | 0.32 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.32 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.32 |
| ▸ | PRKDC | P78527 | 1/20 | 0.31 |
| ▸ | MTOR | P42345 | 1/20 | 0.31 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL861444 | 0.91 | PIK3CA (0.40) | PIK3CAGPR142CREBBP | |
| SCHEMBL3719530 | 0.88 | GPR142 (0.36) | PIK3CAGPR142CREBBPKITAURKA | |
| SCHEMBL856296 | 0.86 | GRIA1 (0.34) | PIK3CAGPR142CREBBPKITAURKA | |
| SCHEMBL13056695 | 0.85 | GPR142 (0.35) | PIK3CAGPR142CREBBPKITAURKA | |
| SCHEMBL858821 | 0.84 | AURKA (0.33) | PIK3CAGPR142CREBBPKITAURKA | |
| SCHEMBL3749918 | 0.83 | PIK3CA (0.37) | PIK3CAGPR142CREBBPAURKAFLT1 | |
| SCHEMBL3760455 | 0.81 | PIK3CA (0.41) | PIK3CAGPR142CREBBPAURKAMTOR | |
| SCHEMBL856829 | 0.80 | GPR142 (0.41) | PIK3CAGPR142CREBBPRIPK1 | |
| SCHEMBL861032 | 0.80 | PIK3CA (0.47) | PIK3CAGPR142CREBBPKIT | |
| SCHEMBL857474 | 0.79 | TNIK (0.37) | PIK3CAGPR142CREBBPKITAURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140080810-A1 | Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture | EXELIXIS, INC. (US) | 2014-03-20 | — | — | US | disclosed |
| EP-2432779-A1 | BENZOXAZEPINES BASED P13K/MT0R INHIBITORS AGAINST PROLIFERATIVE DISEASES | Exelixis, Inc. (US) | 2012-03-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140080810-A1 | Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture | MTOR, RICTOR, PIK3CA | PIK3CA 3/4885GPR142 2004/4885CREBBP 257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.